Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited, plot no.564/a/22, - ledipasvir/ sofosbuvir - tablet - each tablet contains: ledipasvir/ sofosbuvir 90… - sofosbuvir and ledipasvir

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc - 2,4-d as ipa(300g/l) - aqueous - group i herbicide - balansa clover (prior to sowing) | barley | barley - prior to sowing | broom millet | canola (prior to sowing) | cereal rye | ch - amaranth or amaranthus | amsinckia | annual thistle | apple-of-peru | artichoke thistle | australian bindweed - seedling | ball mustard | bathurst burr | bathurst burr - seedling | bellvine - seedling | billygoat weed or blue top | bindweed | bindy-eye | bitou bush or boneseed | blackberry nightshade | blackberry nightshade - seedling | bladder ketmia | blue snakeweed | blue top - ageratum/heliotropium spp. | boxthorn | broadleaf weeds - except noogoora burr | burr medic | californian burr | californian burr seedling | californian thistle | caltrop or yellow vine | caltrop or yellow vine - seedling | camel or afghan melon | canola - brassica napus | cape tulip | capeweed | capeweed - seedling | cat's ear or flatweed | charlock | chinese mint | clockweed | clover | cobbler's pegs | common heliotrope | common iceplant | common storksbill | common vetch or tares | convolvulus vines | cowvine | desiccate broadleaf weeds | dock | dock - seedling | doveweed | fat hen | fleabane | fumitory - red | fumitory - white |

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - estropipate (unii: svi38uy019) (estropipate - unii:svi38uy019) - cream - 1.5 mg in 1 g - ogen vaginal cream is indicated for the treatment of vulval and vaginal atrophy. estrogens should not be used in individuals with any of the following conditions: - known or suspected pregnancy (see boxed warning ). estrogens may cause fetal harm when administered to a pregnant woman. - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - active thrombophlebitis or thromboembolic disorders. ogen vaginal cream (estropipate) is contraindicated in patients hypersensitive to its ingredients.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

gilead sciences, inc, usa - ledipasvir 90mg/sofosbuvir 400mg - tablets - ledipasvir 90 mg/ sofosbuvir 400 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - ledipasvir; sofosbuvir -

Israel - English - Ministry of Health

alexion pharma israel ltd - sebelipase alfa - concentrate for solution for infusion - sebelipase alfa 2 mg / 1 ml - sebelipase alfa - kanuma is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase (lal) deficiency.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

csl limited - taipan snake antivenom; phenol - parenteral liquid/solution/suspension - taipan snake antivenom antivenom-snake active 12000.0 units; phenol phenol other 0.25 %w/v - immunotherapy - animal - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus

United States - English - NLM (National Library of Medicine)

gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - harvoni is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) [see dosage and administration (2.2 and 2.3) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2)] . risk summary if harvoni is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribav

United States - English - NLM (National Library of Medicine)

gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - adult patients : harvoni is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin pediatric patients : harvoni is indicated for the treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with hcv genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis [see dosage and administration (2.3) and clinical studies (14.6)] . if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and ad

United States - English - NLM (National Library of Medicine)

allergan, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e) - pancrelipase lipase 3000 [usp'u] - zenpep® is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects